Table 2.
The effect of 1,25(OH2)D3 and rosiglitazone on osteoclast development in co-culture of non-adherant bone marrow cells and U-33/γ2 cells.
| Treatment | Experiment type 1A | Experiment type 2B | ||||||
|---|---|---|---|---|---|---|---|---|
| 1–3C | 4–19C | >20C | TotalD | 1–3C | 4–19C | >20C | TotalD | |
| V | 25.7±2.1E | 0 | 0 | 25.7±2.1E | 32.0±6.0E | 0 | 0 | 32.0±6.0E |
| R | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D3 | 288.8±25.5 | 162.8±27.3 | 3.0±1.4 | 454.5±18.9 | 325.0±13.7 | 240.3±33.8 | 4.8±1.7 | 570.0±42.3 |
| R+D3 | 166.3±17.4E | 313.5±24.8E | 73.8±6.2E | 553.5±30.5E | 102.5±7.9E | 151.0±7.5E | 24.8±6.4E | 278.3±14.4E |
A
U-33/γ2 cells were pretreated with 10−6 M rosiglitazone for 2 days followed by media change and addition of 10−8 M 1,25(OH2)D3 and non-adherant bone marrow cells followed by TRAP staining after 6 days of growth;
B
Osteoclastogenesis in the presence of 10−6 M rosiglitazone and 10−8 M 1,25(OH2)D3 followed by TRAP staining after 6 days of growth;
C
Number of nuclei per TRAP+ cell;
D
total number of TRAP+ cells per well;
E
p < 0.05 vs D3
V – vehicle; R – rosiglitazone; D3 - 1,25(OH2)D3; R+D3 – rosiglitazone + 1,25(OH2)D3